01—Abstract
Summary
Summary of the 10-K filed February 25, 2021. Cited figures are marked; the original filing is the authoritative source.
Pfizer Inc.'s 2020 10-K report highlights a significant transformation into a focused, innovative biopharmaceutical company following the spin-off of its Upjohn business into Viatris and the formation of the Consumer Healthcare JV.
The company experienced revenue growth of 2% year-over-year, reaching $41.9 billiona, driven by strong performance in key products like Vyndaqel/Vyndamax and Eliquis, despite an estimated $700 million unfavorable impact from the COVID-19 pandemic. Pfizer's research and development efforts remain robust, with notable progress in its COVID-19 vaccine program in collaboration with BioNTech, which received Emergency Use Authorization (EUA) in multiple countries by the end of 2020.
The company's strategic focus on innovation, pipeline advancement, and business development is evident through various collaborations and its commitment to addressing unmet medical needs. While facing typical industry pressures such as pricing and reimbursement challenges and patent expirations, Pfizer's diversified portfolio and strong cash flow position it for continued growth and value creation for shareholders.
02—Key points
Key Highlights
- Revenue increased by 2% to $41.9 billion in 2020, with an operational increase of 3%, despite an estimated $700 million unfavorable impact from the COVID-19 pandemic.
- Completed the spin-off and combination of the Upjohn Business with Mylan to create Viatris, transforming Pfizer into a more focused innovative biopharmaceutical company.
- The Pfizer-BioNTech COVID-19 vaccine (BNT162b2) received EUA in the U.S. in December 2020 and has been authorized in over 50 countries, with projected revenues of approximately $15 billion in 2021.
- Key products like Vyndaqel/Vyndamax, Eliquis, Ibrance, and Xtandi demonstrated strong operational revenue growth.
- Research and Development expenses increased by 12% to $9.4 billion, largely due to collaboration costs for the COVID-19 vaccine and upfront payments for new development programs.
- The company's financial position remains strong, with $14.4 billion in net cash flow from operations and $1.8 billion in cash and cash equivalents as of December 31, 2020.
- Significant business development activities included collaborations with BioNTech, Valneva, CStone, and Myovant, strengthening its pipeline and market position.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2020, Pfizer Inc kept $0.22.
- Revenue$41.65B100.0%
- Cost of revenue−$8.48B20.4%
- Gross profit$33.17B79.6%
- Operating costs−$26.54B63.7%
- Operating income$6.63B15.9%
- Interest, other & tax$2.53B6.1%
- Net income$9.16B22.0%
Where FY2020 revenue went
$41.65B- Other operating costs: $14.94B, 36% of revenue
- SG&A: $11.60B, 28% of revenue
- Cost of revenue: $8.48B, 20% of revenue
- Operating income: $6.63B, 16% of revenue
Kept 16% as operating income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2020filed February 25, 2021Financial Statements
FY2020 against FY2019
| Line item | FY2020FY2019 | Change |
|---|---|---|
| Revenue | $41.65B$40.91B | +1.8% |
| Cost of Revenue | $8.48B$8.05B | +5.3% |
| Gross Profit | $33.17B$32.85B | +1.0% |
| SG&A Expenses | $11.60B$12.73B | −8.9% |
| Operating Income | $6.63B$10.71B | −38.1% |
| Interest Expense | $1.45B$1.57B | −7.9% |
| Net Income | $9.16B$16.03B | −42.8% |
| EPS (Basic) | $1.65$2.88 | −42.7% |
| EPS (Diluted) | $1.63$2.82 | −42.2% |
| Shares Outstanding (Basic) | 5.55B5.57B | −0.3% |
| Shares Outstanding (Diluted) | 5.63B5.67B | −0.8% |
05—Questions
Frequently Asked Questions
What was Pfizer's primary business transformation in 2020?
In 2020, Pfizer completed a significant transformation by spinning off its Upjohn business (primarily off-patent brands and generics) into a new company called Viatris, in combination with Mylan. This strategic move refocused Pfizer to be a more streamlined, science-based biopharmaceutical company concentrating on innovative medicines and vaccines.
How did the COVID-19 pandemic impact Pfizer's financial performance in 2020?
The COVID-19 pandemic had a mixed impact. While it led to an estimated $700 million unfavorable impact on revenue due to disruptions in healthcare visits and lower demand for certain products, it also drove increased demand for certain sterile injectable products and importantly, accelerated the development and authorization of its COVID-19 vaccine, BNT162b2.
What are the key drivers of Pfizer's revenue growth?
Pfizer's revenue growth is driven by its innovative portfolio, particularly products like Vyndaqel/Vyndamax, Eliquis, Ibrance, and Xtandi, which showed strong volume growth and market uptake. The company also leverages strategic collaborations and business development activities to advance its pipeline and expand market reach.
What is the outlook for Pfizer's COVID-19 vaccine?
The Pfizer-BioNTech COVID-19 vaccine (BNT162b2) received Emergency Use Authorization in the U.S. in December 2020 and temporary authorizations in over 50 countries. Pfizer projected approximately $15 billion in revenues from this vaccine in 2021, based on agreements in place at the time of the filing, highlighting its significant impact on future revenue.
06—Continue